RSS-Feed abonnieren
DOI: 10.1055/s-0038-1646972
Age Dependence of Blood Fibrinolytic Components and the Effects of Low-Dose Oral Contraceptives on Coagulation and Fibrinolysis in Teenagers
Publikationsverlauf
Received 06. Mai 1987
Accepted after revision 06. Juli 1988
Publikationsdatum:
30. Juni 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198803/lookinside/thumbnails/10-1055-s-0038-1646972-1.jpg)
Summary
Basal t-PA antigen concentration, PAI-I activity and tibrinolytic capacity was studied in plasma from 20 healthy teenager girls (age 15.9 ± 1.3 years) and two groups of older healthy volunteers, consisting of L7 women (age 32 ± 8 years, group 1) and 35 men (age 34 ± 8 years, group 2). Basal t-PA antigen concentrations in plasma were found to be highly age-dependent with higher values with increasing age. The teenager girls had significantly lower values compared with the two groups of elderly volunteers. PAI-I levels were significantly higher in plasma from the teenager girls and the fibrinolytic capacity after 15 min of venous occlusion was significantly lower.
In this study we also determined the effect of low-dose oral contraceptives (OC) on coagulation and fibrinolysis in the teenager group. Each teenager served as her own control with samples drawn before and on OC after 4 months of use. The coagulation parameters, factor VIII activity, AT III, protein C and platelet counts were all within reference values before and on OC. The fibrinolytic activity in plasma after venous occlusion (15 min) increased significantly when the teenagers had used OC for 4 months. This phenomenon was explained by significantly decreased PAI levels and also by significantly increased t-PA antigen release from the vessel wall after venous occlusion.
-
References
- 1 Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemostas 1984; 52: 127-130
- 2 Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-1455
- 3 Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joet C, Holvoet P, Serradimigni A, Collen D. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemostas 1987; 57: 67-72
- 4 Mannen EF. Oral contraceptives and blood coagulation: A critical review. Am J Obstet Gynecol 1982; 142 (06) 781-790
- 5 Mann JI, Vessey MP, Thorogood M, Doll R. Myocardial infarction in young women with special reference to oral contraceptive practice. Br Med J 1975; 2: 241-245
- 6 Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effect of lowering oestrogen content. Lancet 1980; 11: 1097-1101
- 7 Meade TW. Effects of progestogens on the cardiovascular system. Am J Obstet Gynecol 1982; 142 (06) 776-780
- 8 Pizzo S, Lewis J, Campbell E, Dreyer N. Fibrinolytic response and oral contraceptive associated thromboembolism. Contraception 1981; 23: 181-186
- 9 Jespersen J. Sequential study of plasma euglobulin fibrinolytic activity during the menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-274
- 10 Nilsson IM, Kirkwood TB L, Barrowcliffe TW. In vivo recovery of factor VIII: A comparison of one-stage and two-stage assay methods. Thromb Haemostas 1979; 42: 1230-1239
- 10 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma, as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32 (12) 2160-2165
- 12 Eriksson E, Rånby M, Gyzander E, Risberg B. Determination of plasminogen activator inhibitor in plasma using t-PA and a chromogenic single point poly-D-lysine stimulated assay. Thromb Res 1988; 50: 90-101
- 13 Moroz L, Gilmore NM. A rapid and sensitive 125I-Fibrin solid phase fibrinolytic assay for plasmin. Blood 1975; 46: 543
- 14 Neerstrand H, Östergaard P, Bergqvist D, Matzsch T, Hedner U. t-PA inhibitor, tPA:Ag, Plasminogen and Alpha 2-Antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis 1987; 1: 39-43
- 115 Aillaud MF, Pignol F, Alessi MC, Harle JR, Escande M, Mongin M, Juhan-Vague J. Increase in plasma concentration of plasminogen activator inhibitor, fibrinogen, von Willebrand factor, factor VIII: C and in erythrocyte sedimentation rate with age. Thromb Haemostas 1986; 55: 330-332
- 16 Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. Relationship between age and plasma t-PA, PA-inhibitor, and PA-activity. Thromb Res 1987; 46: 625-633
- 17 Kruithof E KO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70 (05) 1645-1653
- 18 Gevers Leuven JA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-636
- 19 Jespersen J, Kluft C. Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen-levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and Cl-inactivator. Thromb Haemostas 1985; 54: 454-459
- 20 Kjaeldgard A, Larsson B, Astedt B. Regulatory effect of contraceptive steroids on the release of tissue-type plasminogen activator in vitro. Contraception 1984; 30 (04) 355-362
- 21 Jespersen J, Kluft C. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemostas 1986; 55: 388-389
- 22 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75 (03) 818-824
- 23 Emeis JJ, Kooistra T. Interleukin-I and lipopolysaccharide induce a fast-acting inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-1266
- 24 Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-169
- 25 Verheijen JH, Rijken DC, Chang G TG, Preston FE, Kluft C. Modulation of rapid plasminogen activator inhibitor in plasma by stanozolol. Thromb Haemostas 1984; 51: 396-397
- 26 van Hinsbergh V WM, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated Protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65 (02) 444-451
- 27 Sprengers ED, Princen HMG, Kooistra T, van Hinsbergh V WM. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758